Book contents
- Management of Complex Treatment-Resistant Psychotic Disorders
- Management of Complex Treatment-Resistant Psychotic Disorders
- Copyright page
- Contents
- Contributors
- Acknowledgements
- Abbreviations
- List of Icons
- Introduction
- Part I Treatment Strategies
- 1.01 Approaches to Positive Psychotic Symptoms
- 1.02 Use of Plasma Levels in Antipsychotic and Mood Stabilizer Treatment
- 1.03 Advantages of Long-Acting Injectable Antipsychotics
- 1.04 Approach to Treatment-Resistant Schizophrenia Spectrum Patients
- 1.05 Approach to Depressed or Suicidal Schizophrenia Spectrum Patients
- 1.06 Approach to Persistent Aggression and Violence in Schizophrenia Spectrum Psychotic Disorders
- 1.07 Approach to Bipolar Diathesis in Schizophrenia Spectrum Patients
- 1.08 Approach to Anxiety in Schizophrenia Spectrum Patients
- 1.09 Approach to Insomnia and Sleep Disturbance in Schizophrenia Spectrum Disorders
- 1.10 Approach to Psychosis in Children and Adolescents
- 1.11 Electroconvulsive Therapy and Other Non-Pharmacological Treatments
- 1.12 Approach to Substance Use Disorders in Schizophrenia Spectrum Disorders
- 1.13 Approaches to Behavioral Disturbances in Dementia and Traumatic Brain Injury Patients
- Part II Medication Reference Tables
- Appendices
- Index
- References
1.02 - Use of Plasma Levels in Antipsychotic and Mood Stabilizer Treatment
from Part I - Treatment Strategies
Published online by Cambridge University Press: 19 October 2021
Book contents
- Management of Complex Treatment-Resistant Psychotic Disorders
- Management of Complex Treatment-Resistant Psychotic Disorders
- Copyright page
- Contents
- Contributors
- Acknowledgements
- Abbreviations
- List of Icons
- Introduction
- Part I Treatment Strategies
- 1.01 Approaches to Positive Psychotic Symptoms
- 1.02 Use of Plasma Levels in Antipsychotic and Mood Stabilizer Treatment
- 1.03 Advantages of Long-Acting Injectable Antipsychotics
- 1.04 Approach to Treatment-Resistant Schizophrenia Spectrum Patients
- 1.05 Approach to Depressed or Suicidal Schizophrenia Spectrum Patients
- 1.06 Approach to Persistent Aggression and Violence in Schizophrenia Spectrum Psychotic Disorders
- 1.07 Approach to Bipolar Diathesis in Schizophrenia Spectrum Patients
- 1.08 Approach to Anxiety in Schizophrenia Spectrum Patients
- 1.09 Approach to Insomnia and Sleep Disturbance in Schizophrenia Spectrum Disorders
- 1.10 Approach to Psychosis in Children and Adolescents
- 1.11 Electroconvulsive Therapy and Other Non-Pharmacological Treatments
- 1.12 Approach to Substance Use Disorders in Schizophrenia Spectrum Disorders
- 1.13 Approaches to Behavioral Disturbances in Dementia and Traumatic Brain Injury Patients
- Part II Medication Reference Tables
- Appendices
- Index
- References
Summary
Antipsychotic medications represent the pharmacological foundation for the treatment of psychosis and psychomotor agitation. While antipsychotics may be prescribed based on accepted dose ranges, as well as patient response and tolerability, measuring plasma concentrations of antipsychotic medications now represents the standard of care [1].
- Type
- Chapter
- Information
- Publisher: Cambridge University PressPrint publication year: 2021
References
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry, 81(3), 19CS13169.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr, 19, 432–438.CrossRefGoogle ScholarPubMed
Meyer, J. M., Cummings, M. A., Proctor, G., et al. (2016). Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am, 39, 541–556.CrossRefGoogle ScholarPubMed
Castro, V. M., Roberson, A. M., McCoy, T. H., et al. (2016). Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacol, 41, 1138–1143.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2018). Gilman: The Pharmacological Basis of Therapeutics. Pharmacotherapy of Psychosis and Mania. New York: McGraw-Hill.Google Scholar
Letmaier, M., Painold, A., Holl, A. K., et al. (2012). Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol, 15, 739–748.CrossRefGoogle ScholarPubMed
Kim, Y-S., Kim, D. W., Jung, K-H., et al. (2014). Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia. Seizure, 23, 208–212.CrossRefGoogle ScholarPubMed